Can DNA tests match more pancreatic cancer patients to the right drugs?
NCT ID NCT05927298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study enrolls 200 people with pancreatic cancer across Ontario. Researchers collect tumor tissue, blood, and stool samples to perform genetic sequencing and grow mini-tumors in the lab. The goal is to see if this detailed analysis helps more patients receive a treatment matched to their cancer's unique features. This is an observational study, so participants receive standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that genetic and organoid testing helps more pancreatic cancer patients receive treatments tailored to their tumor.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly improve outcomes, and results may take years to influence clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a pill rouse the immune system against pancreatic cancer?
- Can a new ultrasound technique spot hidden pancreatic cancers earlier?